Joe Anderson is the CIO of Arix Bioscience, a leading life science venture capital player with significant commercial and operational expertise. Arix’s primary business objective is focused on the sourcing, financing, development and commercialisation of innovative technologies. Anderson tells us: ‘We’re here for two reasons. One is to make a difference to patients’ lives ultimately. Second is to generate a return for our investors. If we get the products right, if we’re making a difference to people’s health, there will be an economic advantage to our investors.’ The firm has helped firms in oncology (Autolus, Artios, Aura and Harpoon), anti-infectives (Iterum, Amplyx Atox Bio), and gene therapy.